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Background: To evaluate the efﬁcacy of three additional cycles of chemotherapy in patients
with the International Federation of Gynecology and Obstetrics Stage III or IV, who achieved
a complete response after six cycles of intravenous adjuvant paclitaxel/carboplatin after
surgery.
Methods: The clinical data of 94 patients with complete response after six cycles of adjuvant
paclitaxel/carboplatin after surgery between January 1997 and March 2007 were reviewed ret-
rospectively. Three additional cycles using the same chemotherapy were administered to 57
patients as consolidation chemotherapy (Group 1). Thirty-seven patients without the
additional cycles served as controls (Group 2). Disease-free survival (DFS) and overall survi-
val (OS) were evaluated using the Kaplan–Meier method with the log-rank test. The import-
ance of consolidation chemotherapy as a prognostic factor affecting survival was examined
using the Cox’s proportional hazard analysis. The incidence of chemotherapy-induced hem-
atological toxicities was compared between the two groups using chi-square test.
Results: Median DFS and mean OS were not signiﬁcantly different between the two groups
( 1 5v e r s u s2 2m o n t h s ,P ¼ 0.703; 69 versus 73 months, P ¼ 0.891, respectively).
Consolidation chemotherapy was not a prognostic factor of survival although optimal debulk-
ing surgery and lower value of serum CA-125 levels after six cycles of the chemotherapy
were prognostic factors improving DFS (P , 0.01). Grade 3 or 4 leukopenia was more
common in patients treated with consolidation chemotherapy than in those not treated (50.9
versus 21.6%, P ¼ 0.004).
Conclusion: Consolidation chemotherapy using paclitaxel/carboplatin may be inefﬁcient and
relatively toxic to advanced-stage epithelial ovarian cancer patients with complete response
to six cycles of the same chemotherapy after surgery.
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INTRODUCTION
Ovarian cancer is the second most common gynecologic
malignancy with 20 180 new cases and 15 310 deaths each
year in women in the USA (1). The standard treatment for
ovarian cancer consists of staging laparotomy, including
maximal cytoreductive surgery and adjuvant chemotherapy
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doi:10.1093/jjco/hyn034using taxanes and platinum compounds.As a result of pro-
spective trials by the Gynecologic Oncology Group (GOG)
and European–Canadian investigators, paclitaxel and cispla-
tin became a more effective regimen in 1998 (2). However,
carboplatin has been the preferred agent to cisplatin because
gastrointestinal and neurological toxicities of carboplatin
were appreciably lower than those of cisplatin in some
studies, including the GOG protocol 158 (3).
The number of cycles of intravenous adjuvant paclitaxel
and carboplatin seems to be different according to the
International Federation of Gynecology and Obstetrics
(FIGO) criteria for ovarian cancer (4). Treatment with these
drugs every 3 weeks for 3–6 cycles is recommended in
patients with high-grade, high-risk stage I epithelial ovarian
cancer. For those with advanced-stage epithelial ovarian
cancer, intravenous adjuvant paclitaxel and carboplatin every
3 weeks for 6–8 cycles is recommended (5).
Although 50% of patients with advanced-stage epithelial
ovarian cancer achieve a ﬁrst pathologic complete remission
with the ﬁrst treatment course, 90% of suboptimally debulked
patients and 70% of optimally debulked patients relapse in
18–24 months. Improvement of survival should be
approached by making primary adjuvant chemotherapy more
effective or by applying consolidation therapy to patients with
complete response after primary standard treatment (6).
Nevertheless, the role of consolidation chemotherapy is
controversial in advanced-stage epithelial ovarian cancer
patients with complete response after primary standard treat-
ment. Some studies have shown that consolidation che-
motherapy improves survival in patients with complete
response to paclitaxel- and platinum-based chemotherapy
(7,8). On the other hand, consolidation chemotherapy has
been reported to be ineffective for patients with complete
response and increases the incidence of chemotherapy-
induced toxicities, including peripheral neuropathy (9,10).
Furthermore, the role of consolidation chemotherapy has not
yet been completely clariﬁed because previous studies were
performed with various methods of consolidation chemo-
therapy including different routes of administration (intrave-
nous or intraperitoneal), different regimens of chemotherapy
and concurrent radiation therapy.
Therefore, this study was designed to evaluate the efﬁcacy
of three additional cycles of intravenous chemotherapy using
paclitaxel/carboplatin as consolidation chemotherapy in
patients with advanced-stage epithelial ovarian cancer who
achieved complete response after six cycles of the same
chemotherapy.
MATERIALS AND METHODS
PATIENTS
All data of patients for this study were derived from a data-
base of 477 patients who were diagnosed with epithelial
ovarian cancer after staging laparotomy between January
1997 and March 2007. The inclusion criteria were as
follows: patients with a histological conﬁrmation of epi-
thelial ovarian cancer; those who underwent staging laparot-
omy including maximal cytoreductive surgery; those treated
with adjuvant paclitaxel and carboplatin chemotherapy for
six or nine cycles; those with complete response after six
cycles of paclitaxel and carboplatin chemotherapy; Eastern
Co-operative Oncology Group performance states of 0 to 2;
and those without any underlying diseases that may have
affected survival. The current study was approved by the
Institutional Review Board of Seoul National University
Hospital. The requirement for informed consent was waived
because of the retrospective nature of this study.
Patients were required to have adequate bone
marrow, hepatic and renal function, deﬁned as white blood
cells  3000/mm
3, absolute neutrophil counts  1500/mm
3,
platelet counts  75 000/mm
3, hemoglobin levels  8.0 g/dl,
serum bilirubin levels  1.8 mg/dl, serum transaminase
levels  100 IU/l and serum creatinine levels  1.5 mg/dl.
Optimal and suboptimal debulking surgeries were deﬁned
as a residual tumor  1 cm and .1 cm in maximal diameter,
respectively. All patients were classiﬁed according to the
FIGO criteria for ovarian cancer (4), and histological diagno-
sis was performed according to the World Health
Organization (WHO) classiﬁcation.
All patients were then divided into two groups. Patients
were similarly informed of their eligibility to receive three
additional cycles of consolidation chemotherapy; patient
consent to treatment was included in the medical records.
Patients who then received three additional cycles after six
cycles of primary adjuvant chemotherapy were included in
Group 1, whereas patients treated with only six cycles of
adjuvant chemotherapy were included in Group 2.
CHEMOTHERAPY
All patients received intravenous adjuvant paclitaxel and car-
boplatin chemotherapy that started 2–3 weeks after surgery.
The chemotherapeutic regimens consisted of paclitaxel
(135 mg/m
2 for a 24-h infusion period or 175 mg/m
2 for a
3-h infusion period) and carboplatin (AUC 4.5 or 5).
Chemotherapy was repeated every 3 weeks.
EVALUATION OF RESPONSE,D EFINITION OF SURVIVAL AND
TOXICITY CRITERIA
Responses after six cycles of primary adjuvant chemotherapy
were evaluated using appropriate imaging studies, such as
computed tomography (CT), magnetic resonance imaging
(MRI) and positron emission tomography (PET), and serum
CA-125 levels. Serum CA-125 levels were measured within
1 week before staging laparotomy and each cycle of primary
adjuvant chemotherapy. They were measured using a radio-
immunoassay kit (Fujirebio Diagnostics, Malvern, PA, USA)
(11). The upper normal value of serum CA-125 was 37 U/
ml. Since second-look laparotomy has been reported to be
not associated with improvement in clinical outcomes (3),
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difference between baseline and 4 weeks after the com-
pletion of chemotherapy according to the Response
Evaluation Criteria in Solid Tumors (RECIST) and serum
CA-125 levels (12,13). Therefore, a complete response was
deﬁned as the disappearance of all measurable diseases for
at least 4 weeks and the normalization of serum CA-125
levels after ﬁve cycles of the chemotherapy.
Disease-free survival (DFS) was deﬁned as the time that
elapsed from the date after the completion of primary adju-
vant chemotherapy to the date of clinically proven recur-
rence. Overall survival (OS) was calculated as the time from
the date of staging laparotomy to the date of cancer-related
death or the end of study. Hematological toxicities due to
chemotherapy were coded according to the National Cancer
Common Toxicity Criteria (NCI-CTC), version 2.0 (14).
STATISTICAL ANALYSIS
Clinical prognostic factors affecting DFS and OS were
identiﬁed by the use of Cox’s proportional hazard analysis.
DFS and OS between the two groups were evaluated using
the Kaplan–Meier method with the log-rank test. Clinical
characteristics and hematological toxicities were analysed
using the Student’s t-test and chi-square test. Statistical ana-
lyses were performed using SPSS software (Version 12.0;
SPSS Inc, Chicago, IL, USA). A value of P , 0.05 was con-
sidered statistically signiﬁcant.
RESULTS
PATIENTS CHARACTERISTICS
A total of 94 patients with a median age of 52 years (range,
24–79 years) were enrolled in the current study. Among all
patients, 57 were included in Group 1 and 37 in Group
2. Clinicopathologic characteristics of the two groups are
summarized in Table 1. Sixty-two (66.0%) patients were in
menopause. According to the FIGO criteria for ovarian
cancer, two (2.1%) patients were in Stage IIIa, 11 (11.7%) in
Stage IIIb, 73 (77.7%) in Stage IIIc and 8 (8.5%) in Stage
IV. Tumor grade was G1 in 9 (9.6%), G2 in 17 (18.1%) and
G3 in 68 (72.3%) of all patients. Histologically, 77 (81.9%)
tumors were diagnosed as serous carcinoma, nine (9.6%) as
endometrioid carcinoma, ﬁve (5.3%) as clear cell carcinoma,
one (1.1%) as undifferentiated carcinoma and two (2.1%) as
mixed serous and undifferentiated carcinoma.
The median value of serum CA-125 levels before surgery
and after six cycles of primary adjuvant chemotherapy were
765 U/ml (range, 21–300 000 U/ml) and 8 U/ml (range, 5–
37 U/ml), respectively. Pelvic or para-aortic lymph node
sampling or dissection was performed on 54 (57.4%) of all
patients, and lymph node metastasis was identiﬁed in 31
(57.4%). Among all patients, 48 (51.1%) and 46 (48.9%)
patients were classiﬁed into optimal and suboptimal groups,
respectively. CT was performed in 63 (67.0%) patients, MRI
in 7 (7.5%) and PET scan in 24 (25.5%) for the diagnosis of
complete response. When clinical characteristics between the
two groups were compared using the Student’s t-test and
chi-square test, there was a signiﬁcant difference only in age
(P ¼ 0.012) (Table 1).
EVALUATION OF SURVIVAL AND TOXICITY
The median DFS and OS of all patients was 22 months
(range, 1–96 months) and 74 months (range, 6–100
months), respectively. The median DFS in Groups 1 and 2
was 15 and 22 months, respectively (P ¼ 0.703) (Fig. 1). We
calculated mean OS in the two groups because Group 2 did
n o tr e a c hm e d i a nO S .T h em e a nO Si nG r o u p s1a n d2w a s
Table 1. Clinicopathologic characteristics of Groups 1 (nine cycles) and 2
(six cycles)
Characteristics Group 1 (n ¼ 57) Group 2 (n ¼ 37) P value
Age (mean+SD, year) 51.0+9.7 56.3+10.1 0.012
Menopause (n, %) 36 (63.2) 26 (70.3) 0.477
FIGO stage (n, %) 0.078
IIIa–b 5 (8.8) 8 (21.6)
IIIc–IV 52 (91.2) 29 (78.4)
Grade (n, %) 0.188
1 8 (14.0) 1 (2.7)
2 10 (17.5) 7 (18.9)
3 39 (68.4) 29 (78.4)
Pathology (n, %) 0.473
Serous 48 (84.2) 29 (78.4)
Non-serous* 9 (15.8) 8 (21.6)
Residual tumor (n, %) 0.083
1 cm 25 (43.9) 23 (62.2)
.1 cm 32 (56.1) 14 (37.8)
Lymph node involvement
(n,% )
0.475
Yes 23 (40.4) 8 (21.6)
No 15 (26.3) 8 (21.6)
Imaging study for the
diagnosis of complete
response (n,% )
0.598
CT 36 (63.2) 27 (73.0)
MRI 5 (8.8) 2 (5.4)
PET-CT 16 (28.1) 8 (21.6)
Serum CA-125 levels
after six cycles of
chemotherapy (median
with range, U/ml)
8 (5, 37) 7 (5, 36) 0.689
*Non-serous: endometrioid adenocarcinoma (nine cases), clear cell
carcinoma (ﬁve cases), undifferentiated adenocarcinoma (one case), mixed
serous and undifferentiated adenocarcinoma (two cases).
CT, computed tomography; FIGO, International Federation of Gynecology
and Obstetrics; MRI, magnetic resonance imaging; PET, position emission
tomography; SD, standard deviation.
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On multivariate Cox’s proportional hazard analysis, consoli-
dation chemotherapy was not a prognostic factor for DFS
although optimal debulking surgery and lower value of
serum CA-125 levels after six cycles of primary adjuvant
chemotherapy were independent prognostic factors improv-
ing DFS (P , 0.05) (Table 2). However, there was no inde-
pendent prognostic factor for OS (P . 0.05).
When chemotherapy-induced hematological toxicities
were compared between the two groups, Grade 3 or 4 leuko-
penia was more common in patients who were treated with
consolidation chemotherapy than in those who were not
(50.9 versus 21.6%, P ¼ 0.004) (Table 3).
DISCUSSION
The aim of the current study was to evaluate the efﬁcacy of
three additional cycles as consolidation therapy for
advanced-stage epithelial ovarian cancer patients with
Table 2. Multivariate Cox’s proportional hazard analysis for clinical
prognostic factors affecting disease-free survival (DFS) of patients with
complete response after six cycles of primary adjuvant paclitaxel and
carboplatin following staging laparotomy in advanced-stage epithelial
ovarian cancer
Characteristics Hazard ratio 95% conﬁdence
interval
P value
Age (year)
,50 Reference
50 1.319 0.538–3.231 0.545
FIGO stage
IIIa–b Reference
IIIc–IV 0.420 0.063–2.803 0.370
Grade
1 Reference
2 1.706 0.277–10.514 0.565
3 2.691 0.564–12.850 0.214
Histology
Serous Reference
Non-serous* 2.241 0.577–8.699 0.243
Primary adjuvant
chemotherapy (cycles)
6 Reference
9 0.631 0.121–3.292 0.585
Residual tumor (cm)
1 Reference
.1 6.195 1.631–23.528 0.007
Lymph node involvement
No Reference
Yes 1.895 0.591–6.074 0.282
Serum CA-125 levels after
six cycles of primary
adjuvant chemotherapy
1.127 1.045–1.217 0.002
*Non-serous: endometrioid adenocarcinoma (nine cases), clear cell
carcinoma (ﬁve cases), undifferentiated adenocarcinoma (one case), mixed
serous and undifferentiated adenocarcinoma (two cases).
Figure 1. Kaplan–Meier analysis with the log-rank test of disease-free sur-
vival (DFS) between groups 1 (9 cycles) and 2 (6 cycles) (median DFS: 15
versus 22 months, P ¼ 0.703).
Figure 2. Kaplan–Meier analysis with the log-rank test of overall survival
(OS) between groups 1 (9 cycles) and 2 (6 cycles) (mean OS: 69 versus 73
months, P ¼ 0.891).
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carboplatin chemotherapy after staging laparotomy.
Consolidation chemotherapy using paclitaxel/carboplatin
may be inefﬁcient and relatively toxic to advanced-stage epi-
thelial ovarian cancer patients with complete response to six
cycles of the same chemotherapy after surgery. The current
study included some limitations as follows: ﬁrst, the rec-
ommendation of additional chemotherapy in complete
responders’ after six cycles of adjuvant paclitaxel/carboplatin
chemotherapy was different depending upon the physician
because the role of consolidation chemotherapy has been
controversial in previous studies. Thus, patients were classi-
ﬁed into two groups based upon patient consent to additional
consolidation chemotherapy; all patients were similarly
informed of their eligibility for additional chemotherapy but
classiﬁcation was based upon the individual patient’s
decision. Secondly, the number of serous-type epithelial
ovarian cancer is relatively higher than that suggested in a
previous report (52.4%) although serous type is known to be
the most frequent in epithelial ovarian cancer (15). Thirdly,
different imaging studies (CT, MRI or PET) were used for
the evaluation of complete response. However, there was no
signiﬁcant difference in the distribution of selected types of
imaging studies, and survival was not affected by the type of
imaging studies between the two groups (P . 0.05), which
minimized the bias in the current study.
The reason why consolidation chemotherapy has been
important for the management of epithelial ovarian cancer
is that most clinicians expect that extending treatment
beyond the standard six cycles of chemotherapy can
improve survival in epithelial ovarian cancer. Thus,
various methods have been developed, which consist of
different regimens using paclitaxel or platinum agents
(8,16,17), second-line chemotherapy (18,19), intraperitoneal
chemotherapy (20,21), high-dose chemotherapy with
hematopoietic support (22) and whole abdominal radio-
therapy (23).
Nevertheless, no randomized trial with regard to consoli-
dation chemotherapy has provided a statistically signiﬁcant
improvement in OS although a small number of phase II
studies have suggested improved outcomes (24,25). The only
randomized trial with the evidence of clinical beneﬁt was
reported by the Southwest Oncology Group/GOG study of
ovarian cancer patients receiving 3 versus 12 additional
cycles of intravenous paclitaxel following a complete
response to platinum and paclitaxel chemotherapy. The study
showed a progression-free survival (PFS) advantage of 28
versus 21 months in favor of the 12-cycle arm (hazard
ratio ¼ 2.31; 95% conﬁdence interval ¼ 1.08–4.94; P ¼
0.005). Although survival data were not available because of
its early termination by the data safety monitoring commit-
tee, there was no difference in OS between the treatment
arms as of the date of study closure (17).
The current study demonstrated that consolidation che-
motherapy using three additional cycles comprised the best
regimen (intravenous paclitaxel and carboplatin), as primary
adjuvant chemotherapy did not improve DFS and OS in
patients with advanced-stage epithelial ovarian cancer, but
who achieved complete response after six cycles of the same
regimen, supporting the results of previous reports with
regard to the uselessness of consolidation chemotherapy. In
a similar study, three cycle consolidation chemotherapy with
paclitaxel and platinum-based chemotherapy did not provide
a favorable outcome in epithelial ovarian cancer patients
with complete response (26).
Moreover, consolidation chemotherapy may increase toxi-
cities in patients with complete response after primary stan-
dard therapy. Consolidation chemotherapy using weekly
paclitaxel increased the risk for the development of severe
peripheral neuropathy when it was administered for 3–12
cycles (9). Three additional cycles of paclitaxel- and
platinum-based chemotherapy increased Grade 3 or 4 toxici-
ties in patients with complete response after primary treat-
ment although it was statistically insigniﬁcant (26). In the
current study, there was a signiﬁcant increase of Grade 3 or
4 leukopenia in patients who underwent consolidation
chemotherapy (P ¼ 0.004).
In conclusion, prolonged use of the preferred che-
motherapeutic regimen using paclitaxel and carboplatin
may not improve survival in patients with advanced-stage
epithelial ovarian cancer who achieved complete response
after six cycles of the same chemotherapy, and may
increase hematological toxicities, such as Grade 3 or 4
leukopenia.
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Table 3. Chemotherapy-induced hematological toxicities between Groups 1
(nine cycles) and 2 (six cycles)
Chemotherapy-induced
hematologic toxicity
Group 1
(n ¼ 57)
Group 2
(n ¼ 37)
P value
Anemia (n, %) 0.973
Grade 0–2 49 (86.0) 31 (83.8)
Grade 3–4 8 (14.0) 6 (16.2)
Leukopenia (n, %) 0.004
Grade 0–2 28 (49.1) 29 (79.4)
Grade 3–4 29 (50.9) 8 (21.6)
Neutropenia (n, %) 0.396
Grade 0–2 8 (14.0) 9 (24.3)
Grade 3–4 49 (86.0) 28 (75.7)
Thrombocytopenia (n, %) 0.628
Grade 0–2 55 (96.5) 34 (91.9)
Grade 3–4 2 (3.5) 3 (8.1)
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